English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at the UNC School of Medicine have found that a metabolic enzyme called Acetyl-CoA Carboxylase causes T cells to store fat when they are in solid tumors, rather than burning fat for energy.
Tag: chimeric antigen receptor T cell (CAR-T) therapy
Novel bispecific design improves CAR T–cell immunotherapy for childhood leukemia
Findings from St. Jude Children’s Research Hospital showed a novel dual targeting approach, where a single molecule can recognize two potential cancer-related proteins, is more effective than the single targeting approach, preventing immune escape.
Moffitt Researchers Develop CAR T Cells that Fight Prostate Cancer in Bone
Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients. In a new article published today in Science Advances, a team of Moffitt scientists demonstrates that chimeric antigen receptor T-cell (CAR T) therapy is an effective antitumor approach in mouse models of bone metastatic prostate cancer.
New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
Ultrasound remotely triggers immune cells to attack tumors in mice without toxic side effects
A new cancer immunotherapy pairs ultrasound with specially engineered CAR T cells to destroy malignant tumors while sparing normal tissue. The new experimental therapy significantly slowed down the growth of solid cancerous tumors in mice.
Five Years Later: Penn-developed CAR T Therapy Shows Long-lasting Remissions in Non-Hodgkin Lymphomas
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine.
Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel
SEATTLE — Feb. 5, 2021 — Today the U.S. Food and Drug Administration approved the chimeric antigen receptor immunotherapy, Breyanzi (lisocabtagene maraleucel or liso-cel), for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies.The approval was granted to Bristol Myers Squibb, and development of the therapy was supported by physician-scientists at Fred Hutchinson Cancer Research Center.
Penn Medicine Researchers Unlock the Door to Tumor Microenvironment for CAR T Cells
Combining chimeric antigen receptor (CAR) T cell therapy with a PAK4 inhibitor allowed the engineered cells to punch their way through and attack solid tumors, leading to significantly enhanced survival in mice.
Penn Study Supports Use of Radiation Before CAR Therapy for Multiple Myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.
Moffitt Researchers Identify Factors to Predict Severe Toxicities in CAR T Patients
In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers identify possible factors that could help physicians know if patients are at higher risk for severe adverse events before they receive CAR T therapy.
NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy
The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.